Aprea Therapeutics (NASDAQ:APRE) Earns “Outperform” Rating from Wedbush

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a report released on Tuesday,RTT News reports. They presently have a $11.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 402.28% from the stock’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a research report on Wednesday, January 15th.

Aprea Therapeutics Trading Down 3.1 %

Shares of Aprea Therapeutics stock traded down $0.07 during trading on Tuesday, reaching $2.19. The stock had a trading volume of 15,809 shares, compared to its average volume of 18,727. The company has a market capitalization of $11.90 million, a price-to-earnings ratio of -0.78 and a beta of 0.82. The stock has a fifty day moving average price of $3.12 and a two-hundred day moving average price of $3.26. Aprea Therapeutics has a 52 week low of $2.15 and a 52 week high of $6.80.

Aprea Therapeutics (NASDAQ:APRE) last released its earnings results on Tuesday, March 25th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.20. The firm had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.15 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. On average, equities analysts forecast that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Institutional Trading of Aprea Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of APRE. LPL Financial LLC acquired a new position in shares of Aprea Therapeutics during the 4th quarter worth approximately $53,000. Landscape Capital Management L.L.C. bought a new position in shares of Aprea Therapeutics in the fourth quarter valued at $116,000. BNP Paribas Financial Markets bought a new stake in Aprea Therapeutics during the fourth quarter worth $43,000. Finally, Stonepine Capital Management LLC lifted its stake in Aprea Therapeutics by 8.8% in the fourth quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock valued at $491,000 after acquiring an additional 12,047 shares during the last quarter. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.